Pharmacotherapics Advice in Guidelines for COVID-19

• Main Authors: Zhang-Ren Chen, Ying Zhou, Jin Liu, Hong-Wei Peng, Jian Zhou, Hai-Li Zhong, Li-Li Liu, Ming-Fang Lai, Xiao-Hua Wei, Jin-Hua Wen
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-06-01
• Series: Frontiers in Pharmacology
• Subjects: COVID-19; pneumonia; guideline; pharmacotherapy; SARS-CoV-2
• Online Access: https://www.frontiersin.org/article/10.3389/fphar.2020.00950/full

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.